Credits: Canva
Ozempic might have started as a breakthrough diabetes drug but its story has rapidly evolved into into something far more complicated and controversial. Initially used to suppress appetite and aid weight loss, the medication is now being questioned as an increasing number of patients experience incapacitating gastrointestinal side effects that don't necessarily resolve after withdrawing from the therapy. As the line blurs between miracle medication and medical mystery, it's time to move past the hype and question harder what Ozempic is actually doing in the body.
Over the past year, drugs like Ozempic and Wegovy have transformed from prescription treatments for diabetes and obesity into household names. Their popularity has soared not just in clinics but across TikTok and weight-loss forums, lauded for their dramatic slimming results. But as prescriptions rise, so do concerns — and a disturbing new question is gaining traction: Can these medications cause stomach paralysis and relentless vomiting?
The American U.S. Food and Drug Administration (FDA) has confirmed it received reports of these types of symptoms, and in one notable case, a Louisiana woman sued claiming serious gastrointestinal damage from Ozempic and another GLP-1 agonist, Mounjaro. With attention from the media mounting and patient testimonials mounting, let's sort through fact versus fear and examine the science behind the sensational accusations.
In order to get an idea of the possible side effects, it's important to break down how these medications act. Ozempic and Wegovy and their pharmaceutical relatives are members of a group called GLP-1 receptor agonists. They replicate the action of the glucagon-like peptide-1 hormone, a naturally occurring substance secreted by the digestive system after consuming food. The hormone does three primary things: slows gastric emptying, suppresses hunger, and enhances insulin sensitivity.
It's this deceleration of stomach emptying — often referred to as the stomach's "braking system" — that is primarily to blame for both the weight-reduction effects and, perhaps, the concerning side effects being reported by users.
Numerous users have reported nausea, vomiting, diarrhea, and a sense of intense fullness — all symptoms now being linked with gastroparesis, or stomach paralysis. Gastroparesis is an illness where the stomach resides too long in digestion, and although not officially recognized as a direct cause of GLP-1 agonists, case study reports and anecdotal data are growing.
FDA representatives have informed some of the media that they are considering these allegations. In the meantime, doctors such as Dr. Daniel Levinthal have admitted that slowing gastric emptying is a recognized side effect of these medications — something seen in trials and described as such on the drug information leaflets.
Most patients are able to endure these symptoms quite easily, especially if treatment begins with a low dose and is gradually increased. For the very small minority of users — particularly those with preexisting illness such as type 1 diabetes — the stomach slowdown can become more than just an annoyance. It can become a crippling condition.
In the first lawsuit of its type, a woman from Louisiana has filed a suit against the makers of Ozempic and Mounjaro following severe and long-term gastrointestinal damage that she supposedly suffered. According to her, the medications induced stomach paralysis, which resulted in hospitalizations and permanent damage.
Although one court case doesn't establish causation, it raises significant questions about whether current prescription labels reflect fully possible long-term risks particularly because these drugs are being more commonly prescribed for weight control in healthy people.
Cyclic Vomiting Syndrome (CVS) is another condition that's been in the crosshairs of the Ozempic discussion. Unlike gastroparesis, with its chronic symptoms that are usually related to eating, CVS is an episodic illness that hits abruptly with severe bouts of vomiting followed by relatively good periods.
One of the users of Ozempic, according to CNN, reported experiencing CVS despite having discontinued the drug. Experts warn against pinpointing the same directly with GLP-1 drugs. CVS has a multifactorial set of causes from infection to stress and is not necessarily bound by the same biological process as gastroparesis.
Nevertheless, the lines are not clearly drawn. Certain specialists hint that for those with an inborn predisposition to gastrointestinal sensitivity, GLP-1 agonists may be a catalyst, exacerbating already-present problems or revealing underlying disorders.
So, who's at greatest risk? Endocrinologists say that those with type 1 diabetes, earlier gastrointestinal illness, or neuropathy involving the vagus nerve — the nerve that assists in regulating stomach emptying — may be at higher risk of having wild reactions. Type 2 diabetics also undergo these effects but typically with less severe symptoms that diminish over time.
Experts highlight the importance of proper medical monitoring. These drugs are effective agents, but they need close monitoring, particularly with dose escalation. Patients should be taught about diet changes and meal times to minimize side effects.
As telemedicine and online prescriptions become more popular, more individuals are gaining access to weight-loss drugs — but not necessarily in the best of conditions. Specialists emphatically warn against self-medication or procuring these drugs via informal means.
Food habits, underlying illnesses, and other medications all contribute to how a person might react to GLP-1 medications. Skipping meals, eating high-fat meals, or eating hastily can increase gastrointestinal effects. Patients are advised by healthcare providers to:
Novo Nordisk, the maker of Ozempic and Wegovy, asserts that GI side effects are well-established and well-documented, usually mild to moderate, and usually remitting over time. The company points to more than 15 years of clinical data attesting to the safety of their GLP-1 products, including continued post-market surveillance by the FDA.
Still, their public statement acknowledges that gastric emptying delay, nausea, and vomiting are all listed in the drug’s side effect profile, a crucial detail that patients must consider before beginning treatment.
Should you be concerned? Not at all but you should know. As with all drugs, Ozempic and its cousins have risks. For the majority, the side effects are mild and temporary. But for some, particularly those who have preexisting medical conditions, it can be worse.
If you're thinking of or taking a GLP-1 agonist, discuss your history with your doctor, keep an eye out for symptoms, and adjust your lifestyle accordingly. The potential for weight loss should never be at the expense of gut health and making savvy decisions is your best protection.
When strands clog your shower drain or your brush looks full every time you run it through your hair, panic is a natural response. Hair loss, or alopecia, is not just a cosmetic concern; it often hints at something deeper. And yet, thanks to internet half-truths and old wives’ tales, myths about alopecia spread faster than a viral meme. On World Alopecia Day, we turn to experts to separate fact from fiction while spotlighting the hidden medical conditions that might be behind the hair fall.
The good news? “Early diagnosis and treatment of these conditions can help restore hair growth and prevent permanent damage,” he assures.
Myth 1: “Only men experience alopecia.”
“While male pattern baldness is more commonly discussed, women are equally susceptible to alopecia due to hormonal imbalances, thyroid issues, and nutritional deficiencies,” says Dr Gangurde. Yes, ladies lose hair too and not just from brushing too hard.
Myth 2: “Stress alone is responsible for hair loss.”
While stress is definitely not good for your scalp’s health, it is not the lone cause. “Alopecia usually has multiple triggers, including genetics, autoimmune conditions, and underlying medical issues,” explains Dr Gangurde. Translation: stressing about stress causing hair fall might make things worse.
Myth 3: “Alopecia is always permanent and untreatable.”
This one might be the most damaging myth of all. “Many forms of hair loss, especially those caused by hormonal or nutritional factors, are reversible with timely medical intervention,” says Dr Gangurde. PRP therapy, medications, and lifestyle changes can all turn things around if you act early enough.
Do Not Just Shed Tears, Seek Help
If your hair has been thinning or falling out in clumps, resist the urge to DIY it with oils, serums, or social media hacks. “If you experience sudden or persistent hair loss, consult a dermatologist or trichologist promptly,” advises Dr Gangurde. “Early intervention can address the root cause, prevent progression, and in many cases, restore healthy hair growth.” Remember that alopecia is not just a surface-level issue. And with the right diagnosis, it is often more fixable than you think.
Credits: Canva
The 2025 flu season has turned out to be unlike any other in recent memory. This year, the flu season is marked by record-setting infections, multiple viral peaks, vaccine mismatches, and an overstretched healthcare system.
According to the Centers for Disease Control and Prevention (CDC), this year’s influenza activity is the most intense since the 2009 swine flu pandemic, with over 80 million estimated illnesses and rising. What’s driving this intensity, and what should the public know about prevention and symptom management?
Let’s break down what makes this flu season so severe and what it means for your health.
In most years, flu activity in the U.S. typically follows a predictable pattern, starting in October, peaking between December and February, and fading by April. But the 2024–2025 season has defied that rhythm.
Cases surged past the national baseline in December and then, unexpectedly, peaked again in February, a second wave that blindsided doctors and public health experts.
As of March 2025, the CDC had reported an estimated 37 million influenza infections, 480,000 hospitalizations, and 21,000 deaths. Hospitalizations, in fact, reached their highest levels in 15 years.
One key driver? A mismatch between circulating flu strains and this year’s vaccine. The dominant strains: H1N1 and H3N2, accounted for more than 99% of cases.
H3N2, in particular, is known for mutating quickly and evading immune responses, and only about half of circulating H3N2 samples matched well with vaccine antibodies, according to CDC surveillance data.
Another reason this year’s flu is hitting so hard: our immune systems are still catching up.
During the height of the COVID-19 pandemic, widespread masking, social distancing, and school closures suppressed not just SARS-CoV-2 but also seasonal flu and other common respiratory viruses. While that helped in the short term, it reduced community-level immunity over time, especially among children, who typically build natural resistance through repeated exposures.
“Young children who were toddlers or preschoolers during the pandemic missed early exposures to flu viruses,” explained experts at the nonprofit group Families Fighting Flu. “Now they’re in school, more socially active, and more vulnerable.”
The CDC reported a troubling spike in pediatric flu deaths this season with 216 fatalities, making it the deadliest flu season for children outside of a pandemic year. Neurological complications such as seizures and hallucinations also rose among young patients.
Another unusual trend: COVID-19 has taken a back seat this winter
Unlike previous years when COVID-19 variants dominated respiratory illness charts, flu has surged ahead as the top driver of doctor visits and hospitalizations. This could be due to a shift in viral dominance, changing weather patterns, or differences in immunity buildup. According to the CDC, nearly 8% of all outpatient visits are currently for flu-like symptoms, much higher than what’s typical for this time of year.
Vaccine Fatigue and Gaps in Coverage
Vaccination remains the strongest tool we have to fight influenza, but uptake has been stagnant, or worse, declining, in key groups.
As of April 2025:
Barriers like vaccine hesitancy, misinformation, racial and ethnic disparities in healthcare access, and fewer flu shot clinics in rural areas continue to widen the gap.
The 2025 flu has shown typical but often more intense symptoms than in previous years. Here’s what to look out for:
These symptoms may overlap with COVID-19 or RSV, but tend to come on faster and hit harder in flu cases this season.
For most healthy people, flu symptoms begin 1 to 4 days after exposure and typically last about 5 to 7 days. However, fatigue and cough may linger for up to two weeks.
You’re considered most contagious in the first 3 to 4 days after symptoms start but can continue to spread the virus up to a week later. The CDC recommends staying home until you’ve been fever-free for at least 24 hours without medication.
Vaccinated individuals may experience milder or shorter symptoms, but those with underlying conditions, young children, and older adults may have longer recoveries and higher risk of complications.
Yes, especially in people with weakened immune systems, chronic illnesses, or no prior flu immunity.
Possible complications include:
This is why experts stress that prevention remains the best medicine.
Here’s how to lower your risk during the remainder of the 2025 season:
Credits: Canva
A lung cancer diagnosis shatters worlds. It thrusts patients into a whirlwind of fear, confusion, and uncertainty. What now? How will I cope? Is this the end? These questions are inevitable and urgent. Yet, amid the anxiety, many patients harbor a dangerous belief: that if cancer has taken hold, quitting smoking is pointless.
It's not just a myth, it’s dangerous. Newer studies show quitting smoking even after a cancer diagnosis can significantly improve survival, make treatments more effective, and alleviate symptoms. In other words: even after cancer strikes, letting go of cigarettes can save your life.
In many small towns across India, where awareness about cancer and tobacco risks is limited, patients often continue to smoke despite their diagnosis. “Some feel it is too late to stop. Others are too addicted or too hopeless to try,” says Dr. Ruchi Singh, HOD & Senior Consultant of Radiation Oncology at Asian Hospital. This is the kind of thinking that kills from the inside out.
The reality is the opposite. Dr. Singh emphasizes, “We try to explain … it is never too late. If they stop smoking, even after the cancer has started, the treatment becomes more effective. It is one of the most important things they can do for themselves.”
Every cigarette after diagnosis undermines treatment, weakens the body, and shortens survival. But should someone quit even late into their cancer journey their lungs begin to heal, treatments work better, and recurrence becomes less likely.
Global research aligns with Dr. Singh’s clinical advise, a study by IARC and Russian oncologists followed 517 lung cancer patients who smoked at diagnosis. Those who quit within three months lived 22 months longer on average and had 33% lower mortality risk and 30% lower disease progression, regardless of stage or smoking intensity.
The Prospective cohort of the Annals of Internal Medicine confirmed quitting after diagnosis yields meaningful survival benefits.
MUSC Hollings Cancer Center. A Harvard study of nearly 5,600 non-small cell lung cancer (NSCLC) patients found former smokers lived longer than current smokers, suggesting even pre-diagnosis quitting increases survival. Additional studies show quitting at or around diagnosis reduces mortality significantly and improves outcomes across all stages of NSCLC.
Smoking cessation isn’t just beneficial—it is one of the most powerful lifesaving interventions for lung cancer patients.
People tend to discount vaccines or preventive care because success makes the threat invisible. Lung cancer prevention has been a public health battle for decades. Policymakers and physicians worked to reduce smoking rates, and incidence fell. But once a cancer diagnosis arrives, all remission plans depend on a foundation of good habits—like quitting tobacco.
Tobacco smoke introduces toxins, weakens immune function, and diminishes treatment outcomes. Continuing to smoke after diagnosis:
Treatment regimens already overwhelm patients. Quitting smoking under stress and physical duress is tough—but not impossible. With the right support, patients dramatically increase their success odds. Here’s a compassionate roadmap:
Indeed, about 36% of tobacco-linked lung cancer patients manage to quit after diagnosis. Those are lives reclaimed.
Lung cancer still has a stigma. Many see it as self-inflicted. That stigma often delays help—including quitting support. But as Dr. Singh reminds us: “People think cancer means a death sentence. But many cases are treatable, especially if caught early. If someone quits smoking, we see real improvement such as better breathing, better recovery after surgery, and fewer chances of the cancer coming back.”
For patients, oncology teams, and families, smoking cessation after diagnosis isn’t optional—it’s urgent evidence-backed medicine.
A lung cancer diagnosis changes everything, but it does not define what comes next. Quitting smoking—even when the disease has already appeared—creates space for healing, response, and survival. It says, “I’m still here. I’m still fighting."
If you or someone you love is facing lung cancer- quit, today. It doesn’t erase the past—but it can extend the future. Numbers don’t lie: treatment plus quitting smoking can give us 22 more months, more energy, more peace, and a higher chance of beating this disease. Quitting is more than choice. It’s courage. And it is always worth it.
© 2024 Bennett, Coleman & Company Limited